MedTrace Logo

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

NCT02388919 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 439

Last updated 2017-09-18

No results posted yet for this study

Summary

Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.

Conditions

Interventions

DRUG

Anlotinib

Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.

DRUG

Placebo

Basic dosage, take once when limosis in the morning.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Baohui Han, professor · Chest hospital affiliated to Shanghai jiaotong university

  • Kai Lee, professor · Tianjin Medical University Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-26
Primary Completion
2017-01-05
Completion
2017-01-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388919 on ClinicalTrials.gov